Pharmaceuticals, Biotechnology & Life Sciences

Explore how AstraZeneca’s Koselugo approval and German vaccine liability case shape its rare‑disease strategy and financial outlook.

Shanghai Fosun Pharma’s Q4 2025 outlook: steady EPS, a modest revenue lift, and a shift to high‑margin oncology drugs. Discover how the company plans to navigate pricing, patent cliffs, and M&A opportunities in China’s specialty‑drug market.

CSL Limited’s $1.5 billion Kankakee expansion boosts U.S. plasma‑derived therapy and albumin production, driving patient access, job growth and supply‑chain resilience.

Merck KGaA’s Q4 2025 results show modest revenue growth and solid margins, yet investors remain wary amid EU pricing pressure and rising biotech competition.

Pfizer’s shift from COVID to a diversified pipeline—trispecific AD drug, GLP‑1 weight loss in China, and oncology Phase‑3 wins—offers high‑margin growth, but carries regulatory and competitive risks.

New Novo Nordisk‑Hims & Hers deal expands Ozempic and Wegovy access via telehealth, boosting weight‑loss treatment reach while maintaining safety and efficacy standards.

Grifols SA plans a private bond placement to boost liquidity and fund its plasma‑derived therapy growth, while maintaining strong clinical evidence and regulatory compliance.

Incyte’s Zynyz gains a second EU approval for SCAC, boosting market‑access strategy and pricing plans while investors reassess its commercial outlook.

Merck KGaA’s Q4 results show a 3.6 % revenue lift and strong operating gains amid currency headwinds, while its oncology and rare‑disease pipeline, strategic M&A prospects, and value‑based market‑access model set the stage for resilient growth and a…

Discover how Novo Nordisk’s partnership with Hims & Hers reshapes GLP‑1 sales, boosts revenue and strengthens its competitive edge in digital health.